ZO MEDICAL MELAMIN-C Skin Bleaching and Correcting with Vitamin C Hydroquinone

Manufacturer
ZO Skin Health, Inc. | G.S. COSMECEUTICAL USA, INC.
Effective date
2019-03-05
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
legacy-cache
Hydrated at
2026-08-02 00:30:01

Label at a glance#

ProductZO MEDICAL MELAMIN-C Skin Bleaching and Correcting with Vitamin C Hydroquinone
Active ingredientHYDROQUINONE
Label structure10 sections

Indications and uses

For the gradual bleaching of hyperpigmented skin conditions such as cholasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.

Dosage and administration

A thin layer of MELAMIN-C™ (Hydroquinone USP, 4%) Skin Bleaching & Correcting Crème with 20% vitamin C should be applied to the affected area twice daily or as directed by a physician. If no improvement is seen after 8-12 weeks of treatment, use of this product should be discontinued. There is no recommended dosage for pediatric patients under 12 years of age except under the advice and supervision of a physician.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

RX ONLY
FOR EXTERNAL USE ONLY:
NOT FOR OPHTHALMIC USE

DESCRIPTION

DESCRIPTION SECTION

Hydroquinone is 1, 4-benzendiol, with a chemical formula of C6H6O2 and a molecular weight of 110.11.

The structural formula is:

C6H6O2
C6H6O2

Each gram of MELAMIN-C™ (Hydroquinone USP, 4%) Skin Bleaching & Correcting Crème with 20% Vitamin C contains Hydroquinone USP 40mg/gm in a base of ascorbic acid, ascorbyl palmitate, caprylic/capric triglyceride, caprylyl methicone, cetyl PEG/PPG-10/1 dimethicone, cyclotetrasiloxane, dimethicone, dimethicone crosspolymer, tocopheryl acetate, ethoxydiglycol, helianthus annuus (sunflower) seed oil, oleyl alcohol, pluenetia volubilis seed oil, retinyl palmitate, rosmarinus officinalis (rosemary) leaf extract, squalene, tocopherol, zanthoxylum bungeanum fruit extract.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause re-pigmentation of bleached areas, which may be prevented by the use of the sunscreen agents.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the gradual bleaching of hyperpigmented skin conditions such as cholasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Prior history of sensitivity or allergic reaction to hydroquinone or to any other ingredient in this product. The safety of topical hydroquinone use during pregnancy or in children (21 years and under) has not been established.

WARNINGS

WARNINGS SECTION

Hydroquinone is a skin bleaching agent which may produce undesired effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product.

Avoid unnecessary sun exposure, use an effective broad-spectrum sunscreen agent or protective clothing should be worn to cover bleached skin to prevent re-pigmentation from occurring.

Hydroquinone may produce exogenous ochronosis, a gradual blue-black darkening of the skin. If his condition occurs, discontinue treatment and consult your physician.

Avoid contact with eyes and mucous membranes. Keep out of reach of children. In case of accidental ingestion, call a physician or a poison control center immediately.

PRECAUTIONS

PRECAUTIONS SECTION

Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin; check within 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, further treatment is not advised. Close patient supervision is recommended.

Drug Interactions

DRUG INTERACTIONS SECTION

Patients are cautioned on concomitant use of medications that are known to be photosensitizing.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies of hydroquinone in animals have demonstrated some evidence of carcinogenicity. The carcinogenic potential of hydroquinone in humans is unknown.

Pregnancy Category C

PREGNANCY SECTION

Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether topical hydroquinone can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Topical hydroquinone should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when topical hydroquinone is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness for pediatric patients below the age of 12 years have not been established.

Adverse Reactions

ADVERSE REACTIONS SECTION

The following reactions have been reported: dryness and fissuring of paranasal and infraorbital areas, erythema, and stinging. Occasional hypersensitivity (localized contact dermatitis) may develop. If this occurs, the medication should be discontinued, and the physician notified immediately.

Overdosage

OVERDOSAGE SECTION

There have been no system reactions reported from the use of topical hydroquinone. However, treatment should be limited to relatively small areas of the body at one time, since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment.

DRUG DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A thin layer of MELAMIN-C™ (Hydroquinone USP, 4%) Skin Bleaching & Correcting Crème with 20% vitamin C should be applied to the affected area twice daily or as directed by a physician. If no improvement is seen after 8-12 weeks of treatment, use of this product should be discontinued. There is no recommended dosage for pediatric patients under 12 years of age except under the advice and supervision of a physician.

HOW SUPPLIED

HOW SUPPLIED SECTION

MELAMIN-C™ (Hydroquinone USP, 4%) Skin Bleaching & Correcting Crème with 20% Vitamin C is available as follows:

2.99 Oz. (85 g) Bottle / NDC 42851-034-85

1.19 Oz. (34 g) Bottle / NDC 42851-034-34

STORAGE

STORAGE AND HANDLING SECTION

Store at controlled room temperature: 15°-30°C (59°-86°F)

PRINCIPAL DISPLAY PANEL - 85 g Bottle Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

ZO®MEDICAL
BY ZEIN OBAGI MD

NDC 42851-034-85

MELAMIN-C™
Skin Bleaching &
Correcting Crème
with 20% Vitamin C

Hydroquinone USP, 4%

RX ONLY

Net Wt. 85 g / 2.99 Oz.

Principal Display Panel - 85 g Bottle Carton
Principal Display Panel - 85 g Bottle Carton

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 18 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42851-03442851-034-85, 42851-034-34

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 17 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
0ea0540b-782d-d622-e063-6394a90ace9d9a1069df-db5d-4ffd-a2da-9137fb7dd4f32024-01-10Warnings, Adverse reactionsExact identifier
spl set id: 9a1069df-db5d-4ffd-a2da-9137fb7dd4f3

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.